Effect of Palm Sugar on Blood Glucose Concentrations (LIPS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01240837|
Recruitment Status : Completed
First Posted : November 15, 2010
Last Update Posted : March 12, 2012
|Condition or disease||Intervention/treatment||Phase|
|Healthy Adults||Other: Arenga Pinnata Sugar Other: Glucose Other: Sucrose||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||21 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Investigator)|
|Primary Purpose:||Basic Science|
|Official Title:||Investigation of the Glycaemic Index of Arenga Pinnata Palm Sugar|
|Study Start Date :||November 2010|
|Actual Primary Completion Date :||January 2011|
|Actual Study Completion Date :||January 2011|
|Active Comparator: glucose||
50 g glucose given orally 3 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
|Active Comparator: sucrose||
50 g sucrose given orally 1 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
|Experimental: palm sugar||
Other: Arenga Pinnata Sugar
50 g palm sugar given orally 1 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
Other Name: palm sugar
- Blood glucose concentrations [ Time Frame: 2 months ]During the labratory visits subjects will ingest glucose (control), sucrose or palm sugar. At time points 0, 15, 30, 45, 60, 90 and 120 minutes post ingestion blood glucose concentrations will be measured by finger prick blood samples.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01240837
|Wageningen, Gelderland, Netherlands, 6701 BH|
|Principal Investigator:||Lydia Afman, Dr||Wageningen University|